Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115

Benzinga Newsdesk www.benzinga.com Positive 81.4%

Neg 0% Neu 0% Pos 81.4%

Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and raises the price target from $90 to $115.